We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MW151 and HA-WBRT in Patients With Brain Metastases (MW151-102)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05417282
Recruitment Status : Recruiting
First Posted : June 14, 2022
Last Update Posted : July 11, 2022
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Northwestern Medicine
Information provided by (Responsible Party):
ImmunoChem Therapeutics, LLC

Tracking Information
First Submitted Date  ICMJE June 6, 2022
First Posted Date  ICMJE June 14, 2022
Last Update Posted Date July 11, 2022
Actual Study Start Date  ICMJE July 1, 2022
Estimated Primary Completion Date December 14, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 8, 2022)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 28 days ]
To assess the safety and tolerability of oral administration of MW151 in adult patients with brain metastases.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 8, 2022)
  • Reduction in cognitive deterioration [ Time Frame: 6 months ]
    To determine if the addition of MW151 to HA-WBRT standard of care treatment will show a trend towards reduction in cognitive deterioration in patients with brain metastases from solid tumors, as measured by standardized NCF tests.
  • Anti-inflammatory effects [ Time Frame: 6 months ]
    To determine if the addition of MW151 to HA-WBRT will have an impact on plasma levels of proinflammatory cytokines (PIC).
  • Progression-free survival and overall survival [ Time Frame: 6 months ]
    To evaluate intracranial progression-free survival and overall survival following the addition of MW151 to HA-WBRT standard of care treatment for patients with brain metastases.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE MW151 and HA-WBRT in Patients With Brain Metastases
Official Title  ICMJE Safety and Tolerability of MW151 Administered With Hippocampal Avoidant Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases
Brief Summary

HYPOTHESIS: MW151 intervention will attenuate radiation induced cognitive impairment caused by hippocampal-avoidant whole brain radiation therapy (HA-WBRT) for brain metastases.

RATIONALE: There is non-clinical evidence that MW151 reduces brain inflammation and improves neurocognitive outcomes in animal models of radiation therapy induced cognitive dysfunction, and in animal models of other CNS disorders.

PURPOSE: This feasibility trial will study MW151 as a mitigator of cognitive dysfunction caused by HA-WBRT in adult patients with brain metastases from solid tumors, as compared with a control group of patients receiving HA-WBRT and placebo.

Detailed Description

In Part A, 10 subjects will receive MW151 in an open label evaluation. At least 5 of these subjects will be male. For each subject, safety and tolerability data for the first 24 hours will be reviewed prior to the continuation of dosing. Subjects will also be evaluated for safety during week 1, during week 2, and at week 4. Once the data from Part A have been reviewed by the Safety Monitoring Committee (SMC), an additional 30 subjects will be recruited to Part B. These subjects will be randomly assigned to MW151 or placebo in a 1:1 ratio.

In both parts A and B subjects will take study drug (males), or the first daily dose of study drug (females) before HA-WBRT which will be administered once a day (3Gy), five days a week (Monday to Friday) for two weeks, for total of ten treatments and 30 Gy.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Cognitive Dysfunction, Cognitive Disorder
Intervention  ICMJE Drug: MW151
Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
Study Arms  ICMJE
  • Experimental: Part A: Open Label
    10 subjects will receive MW151 in an open label evaluation.
    Intervention: Drug: MW151
  • Experimental: Part B: Randomized, placebo-controlled
    30 subjects will be randomly assigned to MW151 or placebo in a 1:1 ratio.
    Intervention: Drug: MW151
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 8, 2022)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 14, 2024
Estimated Primary Completion Date December 14, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

IInclusion Criteria:

  • A subject will be eligible for inclusion in the study only if all of the following criteria are met:

    1. All patients must be willing to and have the capacity to give written informed consent and have signed and dated the informed consent form in accordance with ICH and GCP guidelines
    2. All patients must be able to speak and understand English proficiently
    3. Histologically or cytologically confirmed diagnosis of a solid tumor malignancy within the past 5 years

      a. If the original histologic proof of malignancy is > 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis)

    4. Brain metastases must be visible on contrast-enhanced MRI

      a. Patients who had undergone radiosurgery or surgical resection and are planning adjuvant HA-WBRT do not have to have visible disease but do need a baseline MRI

    5. Karnofsky performance status 70-100%
    6. Serum creatinine ≤ 3 mg/dL and creatinine clearance ≥ 30 mL/min as determined by Cockcroft-Gault
    7. Negative urine pregnancy test within 14 days of Day 1 for Women of Childbearing Potential
    8. Women of childbearing potential and men with female partners of childbearing potential must have no plans for further conception and must practice adequate contraception

      Exclusion Criteria:

  • A subject will not be eligible for inclusion in the study if any of the following criteria are met:

    1. Subject is lactating or is pregnant
    2. Severe, active co-morbidity, defined as follows:

      1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
      2. Transmural myocardial infarction within the last 6 months
      3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
      4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
      5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    3. Intractable seizures while on adequate anticonvulsant therapy (i.e., more than one seizure per month for the past 2 months)
    4. Clinically significant abnormalities in screening laboratory tests that would affect patient safety as determined by the principal investigator
    5. History of psychiatric disorder requiring ongoing medical management
    6. History of substance abuse including alcohol within past 5 years. Appropriately prescribed medication for the treatment of pain or other symptoms related to the underlying malignancy is acceptable
    7. Chronic kidney disease defined as the presence of significant proteinuria on urinalysis and/or eGFR of <60mL/min, as calculated by the clinical site laboratory
    8. Inability to follow the instructions or an unwillingness to cooperate with study procedures
    9. Known allergy to any component of MW151 or placebo as described in investigator's brochure
    10. Received treatment with and/or planned treatment with systemic chemotherapy within 3 days prior, during, or for at least 3 days after completion of HA-WBRT.

      Concurrent immunotherapy is permitted

    11. Prior whole-brain radiotherapy
    12. Use of chronic short-acting benzodiazepine
    13. Use of NSAIDS or steroids within 3 days prior to dosing
    14. Any reason or opinion of the investigator that would prevent the subject from participation in the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Victor Shifrin, PhD (617) 872-0639 vshifrin@ic-rx.com
Contact: Karen Bowen, RN (859) 396-4655 bowen73@windstream.net
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05417282
Other Study ID Numbers  ICMJE MW151-102
R44CA236382 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party ImmunoChem Therapeutics, LLC
Original Responsible Party Same as current
Current Study Sponsor  ICMJE ImmunoChem Therapeutics, LLC
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • National Cancer Institute (NCI)
  • Northwestern Medicine
Investigators  ICMJE
Principal Investigator: Vinai Gondi, MD Northwestern Medicine
PRS Account ImmunoChem Therapeutics, LLC
Verification Date July 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP